|Title||CHA Biotech Acquires Patent Right Regarding Mesenchymal Stem Cell Isolation|
|- The patent titled “Method for isolating primary mesenchymal stem cells derived from human embryonic stem cells using cell insert culture system”.
- The patent is related to isolation and culture of mesenchymal stem cells derived from human embryonic stem cells. This invention covers effective method for isolating and culturing multipotent mesenchymal stem cells using cell insert culture system that has porous membrane with a pore size of 6 to 12㎛(micrometer).
- With this patent method CHA Biotech expects to isolate and culture cells in a short period of time and at a low cost, whereas Mesenchymal stem cells derived from adult stem cell have limited proliferation ability.
- The present invention will be applied to R&D on cell therapy products for immune modulation and musculoskeletal regeneration.
- CHA Biotech’s patent application 10-2010-0124510 was published by the Korean Intellectual Property Office on July 17, 2017.